Lucia Farotti
A5073838359- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Functional Brain Connectivity Studies
- EEG and Brain-Computer Interfaces
- Parkinson's Disease Mechanisms and Treatments
- Epilepsy research and treatment
- Neurological disorders and treatments
- Neuroscience and Neuropharmacology Research
- Neural dynamics and brain function
- Neurological Disease Mechanisms and Treatments
- Health, Environment, Cognitive Aging
- Pharmacological Effects and Toxicity Studies
- Genetic Associations and Epidemiology
- Bioinformatics and Genomic Networks
- Genetic Neurodegenerative Diseases
- Spine and Intervertebral Disc Pathology
- Nutrition, Genetics, and Disease
- Neuroinflammation and Neurodegeneration Mechanisms
- Visual perception and processing mechanisms
- Blood Pressure and Hypertension Studies
- Frailty in Older Adults
- S100 Proteins and Annexins
- Cancer-related cognitive impairment studies
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Sleep and Wakefulness Research
University of Perugia
2015-2025
Azienda Ospedaliera di Perugia
2021
Ospedale Santa Maria
2014-2019
Hospital de Sant Pau
2017
Abstract Introduction Lumbar puncture (LP) is increasingly performed in memory clinics. We investigated patient‐acceptance of LP, incidence and risk factors for post‐LP complications clinic populations. Methods prospectively enrolled 3868 patients (50% women, age 66 ± 11 years, mini mental state examination 25 5) at 23 used logistic regression analysis using generalized estimated equations to investigate complications, such as typical postlumbar headache (PLPH) back pain. Results A total...
There is a great interest in developing cerebrospinal fluid (CSF) biomarkers for diagnosis and prognosis of Parkinson's disease (PD). CSF alpha synuclein (α-syn) species, namely total oligomeric α-syn (t-α-syn o-α-syn), have shown to be help PD diagnosis. Preliminary evidences show that the combination t-α-syn classical Alzheimer's (AD) biomarkers-β-amyloid 1-42 (Aβ42), tau (t-tau), phosphorylated (p-tau)-differentiate patients from controls, reduced levels Aβ42 represent predictive factor...
Abstract Introduction Within‐person trajectories of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) are not well defined. Methods We included 467 subjects from the BIOMARKAPD study with at least two serial CSF samples. Diagnoses were subjective cognitive decline (n = 75), mild impairment 128), and AD dementia 110), a group cognitively unimpaired 154) also included. measured baseline follow‐up levels total tau (t‐tau), phosphorylated (p‐tau), YKL‐40, neurofilament light...
Abstract Background In the field of Alzheimer's disease ( AD ), validation biomarkers for early diagnosis and use as a surrogate outcome in clinical trials is considerable research interest. Objective To characterize profile genetic, neuroimaging neurophysiological prodromal amnestic mild cognitive impairment aMCI ) patients enrolled IMI WP 5 PharmaCog (also referred to European ADNI study). Methods A total 147 were 13 memory clinics. Patients underwent neuropsychological evaluation,...
The ε4 allele of apolipoprotein E (APOE) gene and increasing age are two the most important known risk factors for developing Alzheimer disease (AD). diagnosis AD based on clinical symptoms alone is to have poor specificity; recently developed diagnostic criteria biomarkers that reflect underlying neuropathology allow better assessment strength associations with AD. Accordingly, we examined global age-specific association between APOE genotype by using A/T/N classification, relying...
Patients with mild cognitive impairment due to Alzheimer’s disease (ADMCI) typically show abnormally high delta (<4 Hz) and low alpha (8–12 rhythms measured from resting-state eyes-closed electroencephalographic (rsEEG) activity. Here, we hypothesized that the abnormalities in rsEEG activity may be greater ADMCI patients than those MCI not AD (noADMCI). Furthermore, they associated diagnostic cerebrospinal fluid (CSF) amyloid–tau biomarkers patients. An international database provided...
Auditory “oddball” event-related potentials (aoERPs), resting state functional magnetic resonance imaging (rsfMRI) connectivity, and electroencephalographic (rsEEG) rhythms were tested as longitudinal biomarkers of prodromal Alzheimer’s di
MicroRNAs (miRNAs) regulate translational inhibition of proteins, but are also detected in body fluids, including cerebrospinal fluid (CSF), where they may serve as disease-specific biomarkers. Previously, we showed differential expression miR-146a, miR-29a, and miR-125b the CSF Alzheimer' s disease (AD) patients versus controls. In this study, aim to confirm these findings by using larger, independent sample cohorts AD controls from three different centers. Furthermore, identify confounding...
The discovery of biomarkers for the onset Alzheimer's disease (AD) is essential modification strategies. To date, AD biomarker studies have focused on brain imaging and cerebrospinal fluid (CSF) changes in amyloid- β (Aβ) peptide tau proteins. While reliable to an extent, this panel could be improved by inclusion novel that optimize sensitivity specificity. In study, we determined whether CSF levels nerve growth factor (NGF) precursor protein, proNGF, increased during progression AD,...
.Introduction Despite epilepsy has been associated with cognitive decline, neuropsychological, neurobiological and neurophysiological features in patients late-onset of unknown etiology (LOEU) are poorly known. This cross-sectional study aimed at investigating neuropsychological profile, cerebrospinal fluid (CSF) biomarkers Alzheimer’s disease (AD), resting-state quantitative electroencephalographic (qEEG) cortical rhythms LOEU mild impairment (LOEU-MCI) normal cognition (LOEU-CN), compared...
The variability of Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers undermines their full-fledged introduction into routine diagnostics and clinical trials. Automation may help to increase precision decrease operator errors, eventually improving the diagnostic performance. Here we evaluated three new CSF immunoassays, EUROIMMUNtrademark amyloid-β 1-40 (Aβ1-40), 1-42 (Aβ1-42), total tau (t-tau), in combination with automated analysis samples. were measured a cohort consisting AD...